Femoston-conti 0.5mg/2.5mg tablets

Страна: Великобритания

Език: английски

Източник: MHRA (Medicines & Healthcare Products Regulatory Agency)

Активна съставка:

Estradiol; Dydrogesterone

Предлага се от:

Viatris UK Healthcare Ltd

INN (Международно Name):

Estradiol; Dydrogesterone

дозиране:

500microgram ; 2.5mg

Лекарствена форма:

Oral tablet

Начин на приложение:

Oral

Клас:

No Controlled Drug Status

Вид предписание :

Valid as a prescribable product

Каталог на резюме:

BNF: 06040101; GTIN: 8002660009203

Листовка

1106236
1106236_d1
PROCESS BLACK
FRONT
PACKAGE LEAFLET:
INFORMATION FOR THE USER
Femoston
®
conti 0.5 mg /2.5 mg,
film-coated tablets
Active substances: estradiol/dydrogesterone
Read all of this leaflet carefully before you start
taking this medicine because it contains important
information for you.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or
pharmacist.
-
This medicine has been prescribed for you only. Do
not pass it on to others. It may harm them, even if their
signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or
pharmacist. This includes any possible side effects
not listed in this leaflet. See section 4.
The
full
name
of
your
medicine
is
Femoston-conti
0.5 mg/2.5 mg. In this leaflet the shorter name Femoston-
conti is used.
What is in this leaflet:
1. What Femoston-conti is and what it is used for
2. What you need to know before you take Femoston-conti
3. How to take Femoston-conti
4. Possible side effects
5. How to store Femoston-conti
6. Contents of the pack and other information
1. What FEMOSTON-CONTI is and what it is used for
Femoston-conti is a Hormone Replacement Therapy (HRT).
It contains two types of female hormones, an oestrogen
called estradiol and a progestogen called dydrogesterone.
Femoston-conti is used in postmenopausal women with at
least 12 months since their last natural period.
Femoston-conti is used for
Relief
of
symptoms
occurring
after
menopause
During the menopause, the amount of the oestrogen
produced by a woman’s body drops. This can cause
symptoms such as hot face, neck and chest (“hot flushes”).
Femoston-conti alleviates these symptoms after menopause.
You will only be prescribed Femoston-conti if your symptoms
seriously hinder your daily life.
2. What you need to know before you take FEMOSTON-
CONTI
Medical history and regular check-ups
The use of HRT carries risks which need to be considered
when deciding whether to start taking it, or whether to
carry on taking it.
Th

Данни за продукта

OBJECT 1
FEMOSTON-CONTI 0.5MG/2.5MG
Summary of Product Characteristics Updated 01-Sep-2016 | Mylan
Products Limited
1. Name of the medicinal product
Femoston-conti 0.5 mg/2.5 mg film-coated tablets
2. Qualitative and quantitative composition
28 tablets, each containing 0.5 mg 17β-estradiol (as hemihydrate) and
2.5 mg dydrogesterone.
Excipient with known effect: lactose monohydrate 117.4 mg
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet
A round, biconvex, marked 379 on one side.
(7mm).
Yellow 0.5/2.5 mg tablets.
4. Clinical particulars
4.1 Therapeutic indications
Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in
postmenopausal women at
least 12 months since last menses.
The experience in treating women older than 65 years is limited.
4.2 Posology and method of administration
Femoston-conti 0.5 mg/2.5 mg is a continuous combined HRT for oral
use.
The oestrogen and the progestogen are given every day without
interruption.
The dosage is one tablet per day for a 28 day cycle.
Femoston-conti 0.5 mg/2.5 mg should be taken continuously without a
break between packs.
For initiation and continuation of treatment of postmenopausal
symptoms, the lowest effective dose for
the shortest duration (see also section 4.4) should be used.
Continuous combined treatment may be started with Femoston-conti 0.5
mg/2.5 mg depending on the
time since menopause and severity of symptoms. Women experiencing a
natural menopause should
commence treatment with Femoston-conti 0.5 mg/2.5 mg not earlier than
at least 12 months after their
last natural menstrual bleed. For surgically induced menopause,
treatment may start immediately.
Depending on the clinical response, the dosage can subsequently be
adjusted.
Patients changing from a continuous sequential or cyclical preparation
should complete the 28 day cycle
and then change to Femoston-conti 0.5 mg/2.5 mg.
Patients changing from another continuous combined preparation may
start therapy at any time
If a dose has been forgotten, it